Results 151 to 160 of about 3,560 (171)
Some of the next articles are maybe not open access.
Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia
Hämostaseologie, 2019AbstractManagement of patients with corticosteroid-refractory immune thrombocytopaenia (ITP) possesses a significant challenge to practitioners. Until recently, options included splenectomy and immunosuppression. With improved knowledge of both thrombopoiesis and the pathophysiology of ITP, novel drug development with thrombopoietin-receptor agonists ...
openaire +2 more sources
Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease
Seminars in Thrombosis and Hemostasis, 2020AbstractThrombocytopenia is one of the most common hematologic complications in cirrhosis. Despite limited data linking platelet count and bleeding risk in patients with cirrhosis, the use of platelets transfusions for invasive procedures has been a common practice. Recently, thrombopoietin (TPO) receptor agonists have been approved for use in patients
Saro, Khemichian, Norah A, Terrault
openaire +2 more sources
Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics
HämostaseologieAbstractThis review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S.
Jennifer, Gebetsberger +2 more
openaire +2 more sources
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
Experimental Hematology, 2005Peptide and other small molecule agonists have been described for several cytokines and growth factors. Hydrazone compounds described here as thrombopoietin receptor agonists were identified as activating STAT proteins in a Tpo responsive cell line.STAT activation and analysis of signal transduction pathways in cell lines and normal human platelets was
Connie L, Erickson-Miller +12 more
openaire +2 more sources
Cytomegalovirus‐associated thrombocytopenia treated with thrombopoietin receptor agonist
Internal Medicine Journal, 2016Symptomatic cytomegalovirus (CMV) in immunocompetent individuals is an uncommon, yet recognised, phenomenon. This report discusses a case of CMV‐associated thrombocytopenia refractory to immunomodulation and antivirals. Ultimately, a clinicopathological response was attained with eltrombopag.
J. D. Simpson +3 more
openaire +2 more sources
Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine
Science, 1997Two families of small peptides that bind to the human thrombopoietin receptor and compete with the binding of the natural ligand thrombopoietin (TPO) were identified from recombinant peptide libraries. The sequences of these peptides were not found in the primary sequence of TPO.
S E, Cwirla +14 more
openaire +2 more sources
Therapeutic Use of Thrombopoietin Receptor Agonists
2017Discoveries throughout the twentieth century have forged our understanding of platelet production and including the variables involved in regulating the growth and maturation of megakaryocytes (Kuter, Br J Haematol 165:248–58, 2014). Thrombopoietin (TPO) is the premier growth factor involved in platelet production.
Michael D. Tarantino, Sarah Chalmers
openaire +1 more source
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia
The Lancet Haematology, 2022Maria L, Lozano, Francesco, Rodeghiero
openaire +2 more sources
Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era
Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021Giuseppe Lassandro +2 more
exaly